DIGEST

Summary

This episode covers significant advancements in oncology biotech, including Isomorphic Labs' $2.1 billion funding, Blackstone's $250 million investment in Anagram Therapeutics, breakthroughs in overcoming chemotherapy resistance with the NP137 antibody, and the emergence of HIF2α inhibitors as viable therapeutic targets. We also discuss the paradigm shift toward bladder preservation in muscle-invasive bladder cancer (MIBC).